Ovid Therapeutics Files Q1 2025 10-Q
Ticker: OVID · Form: 10-Q · Filed: 2025-05-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Ovid Therapeutics filed its Q1 2025 10-Q. Financials look steady.
AI Summary
Ovid Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including common stock and preferred stock activity. The company's principal executive offices are located at 441 Ninth Avenue, 14th Floor, New York, NY 10001.
Why It Matters
This filing provides investors with the latest financial performance and structural details of Ovid Therapeutics, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report and does not contain immediate red flags.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250513 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 441 NINTH AVENUE, 14TH FLOOR (address) — Company's business and mailing address
- NEW YORK, NY 10001 (address) — Company's business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 13, 2025.
What is the primary business address of Ovid Therapeutics Inc.?
The primary business address of Ovid Therapeutics Inc. is 441 Ninth Avenue, 14th Floor, New York, NY 10001.
What is the fiscal year end for Ovid Therapeutics Inc.?
The fiscal year end for Ovid Therapeutics Inc. is December 31.
What type of stock activity is mentioned for the period ending March 31, 2025?
The filing mentions activity related to Series A Preferred Stock and Common Stock for the period ending March 31, 2025.
From the Filing
0001628280-25-024913.txt : 20250513 0001628280-25-024913.hdr.sgml : 20250513 20250513080823 ACCESSION NUMBER: 0001628280-25-024913 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250513 DATE AS OF CHANGE: 20250513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 25937255 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 10-Q 1 ovid-20250331.htm 10-Q ovid-20250331 0001636651 12-31 2025 Q1 false 0.33 0.33 0.33 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure ovid:Investment utr:sqft ovid:vote ovid:product ovid:segment 0001636651 2025-01-01 2025-03-31 0001636651 2025-05-09 0001636651 2025-03-31 0001636651 2024-12-31 0001636651 2024-01-01 2024-03-31 0001636651 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0001636651 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001636651 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001636651 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001636651 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2024-12-31 0001636651 us-gaap:CommonStockMember 2024-12-31 0001636651 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001636651 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001636651 us-gaap:RetainedEarningsMember 2024-12-31 0001636651 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001636651 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001636651 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001636651 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001636651 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2025-03-31 0001636651 us-gaap:CommonStockMember 2025-03-31 0001636651 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001636651 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001636651 us-gaap:RetainedEarningsMember 2025-03-31 0001636651 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2023-12-31 0001636651 us-gaap:CommonStockMember 2023-12-31 0001636651 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001636651 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001636651 us-gaap:RetainedEarningsMember 2023-12-31 0001636651 2023-12-31 0001636651 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001636651 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001636651 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001636651 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001636651 us-gaap:PreferredStockMember us-gaap:ConvertiblePreferredStockMember 2024-03-31 0001636651 us-gaap:CommonStockMember 2024-03-31 0001636651 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001636651 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001636651 us-gaap:RetainedEarningsMember 2024-03-31 0001636651 2024-03-31 0001636651 2014-04-01 2025-03-31 0001636651 ovid:GensaicIncMember 2025-03-31 0001636651 ovid:GensaicIncMember 2024-12-31 0001636651 ovid:GravitonBioscienceCorporationMember 2024-12-31 0001636651 ovid:GravitonBioscienceCorporationMember 2025-03-31 0001636651 ovid:GravitonBioscienceCorporationMember 2025-01-01 2025-03-31 0001636651 ovid:GravitonBioscienceCorporationMember 2024-01-01 2024-03-31 0001636651 ovid:MarinusTherapeuticsIncMember 2024-12-31 0001636651 ovid:MarinusPharmaceuticalsIncMember 2025-02-01 2025-02-28 0001636651 us-gaap:FairValueInputsLevel1Member ovid:MoneyMarketFundsAndShortTermInvestmentsMember 2025-03-31 0001636651 us-gaa